Evolus

Evolus company information, Employees & Contact Information

Explore related pages

Related company profiles:

Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. At Evolus, you have the opportunity to be part of a movement. A performance beauty company changing the game. We are bringing innovation and forward-thinking technology to an industry desperately wanting frictionless experiences. Our work disrupts the status quo, but most importantly, we will make an impact, we are customer-centric - always. Because of this, we are excited to step through the door each morning. We help each other climb; we don't climb over one another. We believe that integrity and a team-driven environment connect entrepreneurial minds. Getting goose bumps? Good. Join the Evolus movement, and let's see where you can put your talents to work.

Company Details

Employees
410
Founded
-
Address
520 Newport Center Dr, Newport Beach,california 92660,united States
Industry
Wellness And Fitness Services
NAICS
Fitness and Recreational Sports Centers
Website
evolus.com
Keywords
Newport Beach.
HQ
Newport Beach, California
Looking for a particular Evolus employee's phone or email?

Evolus Questions

News

Evolus to Participate in 2025 Stifel Healthcare Conference - Yahoo Finance

Evolus to Participate in 2025 Stifel Healthcare Conference Yahoo Finance

Evolus to Report Third Quarter Financial Results on November 5, 2025 - Yahoo Finance

Evolus to Report Third Quarter Financial Results on November 5, 2025 Yahoo Finance

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins - Yahoo Finance

Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins Yahoo Finance

Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp - Business Wire

Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp Business Wire

Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer - Yahoo Finance

Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer Yahoo Finance

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France - Yahoo Finance

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France Yahoo Finance

Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates - Yahoo Finance

Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates Yahoo Finance

Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels - Yahoo Finance

Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels Yahoo Finance

Evolus Reports First Quarter 2025 Results - Yahoo Finance

Evolus Reports First Quarter 2025 Results Yahoo Finance

Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility - Yahoo Finance

Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility Yahoo Finance

Evolus Announces Commercial Launch of Evolysse™ - Yahoo Finance

Evolus Announces Commercial Launch of Evolysse™ Yahoo Finance

Evolus Launches "Drop the F Word" Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels - Yahoo Finance

Evolus Launches "Drop the F Word" Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels Yahoo Finance

Evolus Announces Departure of its Chief Financial Officer - Business Wire

Evolus Announces Departure of its Chief Financial Officer Business Wire

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance - Yahoo Finance

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance Yahoo Finance

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels - Yahoo Finance

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels Yahoo Finance

Evolus Unleashes Major Talent Expansion: 34 New Hires Secure Equity Stakes in Growth Push - Stock Titan

Evolus Unleashes Major Talent Expansion: 34 New Hires Secure Equity Stakes in Growth Push Stock Titan

Evolus Reports Third Quarter 2024 Results - Business Wire

Evolus Reports Third Quarter 2024 Results Business Wire

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers - Business Wire

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers Business Wire

Evolus Unveils New Branding for Flagship Product Jeuveau® to Reflect Growing and Evolving Consumers - Business Wire

Evolus Unveils New Branding for Flagship Product Jeuveau® to Reflect Growing and Evolving Consumers Business Wire

Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock - Business Wire

Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock Business Wire

Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer - Business Wire

Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer Business Wire

Evolus to Participate in the Barclays Global Healthcare Conference - Business Wire

Evolus to Participate in the Barclays Global Healthcare Conference Business Wire

Evolus to Participate in the SVB Securities Global Biopharma Conference - Business Wire

Evolus to Participate in the SVB Securities Global Biopharma Conference Business Wire

Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024 - The AI Journal

Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024 The AI Journal

Evolus Receives Regulatory Approval for Nuceiva® in Australia - Business Wire

Evolus Receives Regulatory Approval for Nuceiva® in Australia Business Wire

Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update - Business Wire

Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update Business Wire

“Extra-Strength” Dose for Extended Duration Study at 2023 IMCAS World Congress - Business Wire

“Extra-Strength” Dose for Extended Duration Study at 2023 IMCAS World Congress Business Wire

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue Aspiration - Business Wire

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue Aspiration Business Wire

Evolus Launches New Campaign Inspiring Consumers to “Switch Your Tox and Love Evolus Forever” - Business Wire

Evolus Launches New Campaign Inspiring Consumers to “Switch Your Tox and Love Evolus Forever” Business Wire

Evolus to Participate in November Investor Conferences - FinancialContent

Evolus to Participate in November Investor Conferences FinancialContent

Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting - The AI Journal

Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting The AI Journal

Evolus Provides Update on United States International Trade Commission (ITC) Case - GlobeNewswire

Evolus Provides Update on United States International Trade Commission (ITC) Case GlobeNewswire

Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences | User | statesmanexaminer.com - FinancialContent

Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences | User | statesmanexaminer.com FinancialContent

Evolus Receives Approval for Nuceiva™ in the European Union - GlobeNewswire

Evolus Receives Approval for Nuceiva™ in the European Union GlobeNewswire

Evolus Receives FDA Approval for Jeuveau™ prabotulinumtoxinA-xvfs for Injection - GlobeNewswire

Evolus Receives FDA Approval for Jeuveau™ prabotulinumtoxinA-xvfs for Injection GlobeNewswire

Evolus and Clarion Medical Technologies Announce First - GlobeNewswire

Evolus and Clarion Medical Technologies Announce First GlobeNewswire

Evolus Announces First Shipment of Jeuveau™ (prabotulinumtoxinA-xvfs) to Customers in the United States - GlobeNewswire

Evolus Announces First Shipment of Jeuveau™ (prabotulinumtoxinA-xvfs) to Customers in the United States GlobeNewswire

Evolus, Inc. Announces Pricing of Initial Public Offering of Common Stock - PR Newswire

Evolus, Inc. Announces Pricing of Initial Public Offering of Common Stock PR Newswire

Top Evolus Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant